Financial Engines Advisors L.L.C. Takes $384,000 Position in Pfizer Inc. (NYSE:PFE)

Financial Engines Advisors L.L.C. bought a new position in shares of Pfizer Inc. (NYSE:PFE) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 14,483 shares of the biopharmaceutical company’s stock, valued at approximately $384,000.

Other hedge funds have also added to or reduced their stakes in the company. Nordea Investment Management AB increased its position in shares of Pfizer by 36.1% in the fourth quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company’s stock valued at $108,002,000 after acquiring an additional 1,080,822 shares during the last quarter. Parsons Capital Management Inc. RI grew its stake in shares of Pfizer by 118.7% in the fourth quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company’s stock valued at $7,820,000 after buying an additional 159,984 shares in the last quarter. NFJ Investment Group LLC increased its holdings in Pfizer by 12.8% during the third quarter. NFJ Investment Group LLC now owns 384,571 shares of the biopharmaceutical company’s stock worth $11,129,000 after buying an additional 43,719 shares during the last quarter. Copley Financial Group Inc. acquired a new stake in Pfizer in the third quarter valued at $577,000. Finally, Zacks Investment Management lifted its stake in Pfizer by 10.9% in the third quarter. Zacks Investment Management now owns 2,389,138 shares of the biopharmaceutical company’s stock valued at $69,142,000 after acquiring an additional 235,243 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 0.6 %

Shares of NYSE PFE opened at $25.05 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The company has a market cap of $142.08 billion, a price-to-earnings ratio of 17.77, a PEG ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The stock has a 50-day moving average price of $26.09 and a two-hundred day moving average price of $26.97.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm’s revenue was up 24.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.10 EPS. As a group, analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on PFE shares. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Citigroup dropped their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Truist Financial reduced their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Guggenheim restated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, Bank of America reaffirmed a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $31.92.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the firm’s stock in a transaction dated Thursday, February 13th. The stock was bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. 0.06% of the stock is currently owned by company insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.